Vivus VVUS

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Arena Pharmaceuticals' Belviq Sales Dip - Why?

      Headlines

      Mon, 21 Apr 2014

      By Spencer Osborne : Belviq, the anti-obesity drug from Arena Pharmaceuticals ( ARNA ), saw sales fall over 10% last week according to industry tracking services IMS Health and Symphony Health. The dip in sales had many confused, but the reason behind the shift in sales is likely due to a pretty ...

    2. What Arena's Belviq Television Ad Campaign Means For The Stock

      Headlines

      Mon, 14 Apr 2014

      By Spencer Osborne : The weight loss drug Belviq from Arena Pharmaceuticals ( ARNA ) is now being promoted on television with a national advertising campaign . This is a day that many long term investors have been waiting for. Can the emergence of a television ad campaign help sales of Belviq, and

    3. Arena - Belviq Sales Up Modestly Heading Into Television Ads

      Headlines

      Fri, 11 Apr 2014

      By Spencer Osborne : It is certainly an interesting time to be an investor in Arena Pharmaceuticals ( ARNA ). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way. The biggest challenges that Belviq faces are insurance

    4. Three Vivus directors won't stand for re-election

      Headlines

      Tue, 8 Apr 2014

      Vivus ( VVUS ) directors J. Martin Carroll, Robert N. Wilson, and Mark B. Logan ..... June 20 annual meeting. ( 8-K ) Carroll, Wilson, and Logan were all on Vivus ' board prior to the end of a bitter proxy fight with First Manhattan and

    5. Premarket Gainers / Losers

      Headlines

      Thu, 3 Apr 2014

      Gainers: AMRS +14% . CYTR +10% . MNGA +7% . CPRX +7% . CTRP +5% . Losers: SGOC -32% . BGMD -18% . LQDT -13% . APPY -12% . BKS -9% . [[PBR-A]] -6% . VVUS -5% . Post your comment!

    6. Vivus gets slapped

      Headlines

      Thu, 3 Apr 2014

      Piper Jaffray downgrades Vivus ( VVUS ) to Underweight with a PT of $3.00. Shares are down 5% to $5.85 premarket on 107K shares. Consensus estimates for Q1

    7. Can Stendra Cure Vivus

      Headlines

      Tue, 1 Apr 2014

      near 52 week lows? Investors in Vivus ( VVUS ) certainly hope so, and there are ..... erectile dysfunction drug Stendra. Vivus and its marketing partner Auxilliam ..... sales could really get impressive. Vivus had put a lot of hope into the anti-obesity

    8. Arena - Scripts, Ads, Sales Reps

      Headlines

      Fri, 28 Mar 2014

      television ads will be the first from the either Arena or Vivus ( VVUS ) since Belviq and Qsymia entered the market. The prescription ..... its challenges. Qsymia, the anti-obesity drug from Vivus , has been on the market well over a year and has stalled

    9. Vivus : Shares Are Oversold, Pressure Is On To Secure A Commercial Partner And Drive Market Penetration

      Headlines

      Wed, 26 Mar 2014

      Investor : Company Description: Vivus ( VVUS ) is a Mountain View, CA based biopharma ..... and the subsequent FDA withdrawal , Vivus was required to conduct three large ..... in certified retail pharmacies. Vivus second product is Avanafil, which

    10. Arena Down With Overall Market - Sales Data No Help

      Headlines

      Mon, 17 Mar 2014

      By Spencer Osborne : As we head toward the end of the first quarter, and the fiscal year end for Arena's ( ARNA ) marketing partner Eisai ( OTCPK:ESALY ), it is appropriate to assess where we are for both companies in terms of the sales for the anti-obesity drug Belviq. As it happens, this week's

    « Prev12345Next »
    Content Partners